Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

Molecular Cancer Therapeutics

Volumn 4, Issue 5, 2005, Pages 787-798

  Zhu, Lijun ^a,b   Somlo, George ^a   Zhou, Bingsen ^a   Shao, Jimin ^a,b   Bedell, Victoria ^a   Slovak, Marilyn L ^a   Liu, Xiyong ^a   Luo, Jianhong ^b   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CASPASE 2; CASPASE 6; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLICE INHIBITORY PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6 RECEPTOR; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN MCL 1; RAF PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN MICROARRAY; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; UNINDEXED SEQUENCE;

APOPTOSIS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 15744392410     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0330     Document Type: Article

References (44)

1. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16-3;q32.3) in multiple myeloma: association with increased expression and activating mutation of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-4.
2. Martin GR. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 1998;12:1571-86.
3. Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Molecular biology of the cell 2001;12:931-42.
4. Kanai M, Goke M, Tsunekawa S, Podolsky DK. Signal transduction pathway of human fibroblast growth factor receptor 3: identification of a novel 66-kDa phosphoprotein. J Biol chem 1997;272:6621-8.
5. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97:729-36.
6. Otsuki T, Yamada O, Yata K, et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32.3) and FGFR3 translocation. Int J Oncol 1999;15:1205-12.
7. Ronchetti D, Greco A, Compasso S, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001;20: 3553-62.
8. Soverini S, Terragna C, Testoni N, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 2002;87:1036-40.
9. Li Z, Zhu YX, Plowright EE, et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001;97:2413-9.
10. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95:992-8.
11. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520-9.
12. Dvorak P, Dvorakova D, Doubek M, et al. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia 2003;17:2418-25.
13. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab 2003;80:121-8.
14. Qian SX, Somlo G, Zhou B, et al. Ribozyme cleavage leads to decreased expression of fibroblast growth factor 3 in human multiple myeloma cells, which is associated with apoptosis and down-regulation of vascular endothelial growth factor. Oligonucleotides 2005;15:1-11.
15. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and STAT activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19:3309-20.
16. Sharp PA. RNA interference. Genes Dev 2001;15:485-90.
17. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 2002;30:1757-66.
18. Ji J, Wernli M, Klimkait T, Erb P. Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett 2003; 552:247-52.
19. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
20. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67.
21. Miguel-Garcia A, Orero T, Matutes E, et al. F. bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 1998 Apr;83:298-304.
22. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13:289-94.
23. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002;99:1885-93.
24. Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004;103:1799-806.
25. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
26. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
27. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84.
28. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
29. Berensan JR, Ma HM, Vescio R. The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28: 626-33.
30. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-79.
31. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
32. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001;97:1817-22.
33. Chen YH, Lavelle D, DeSimone J, Uddin S, Platnnias LC, Hankewych M. Growth inhibition of a human myeloma cell line by all- trans retinoic acid is not mediated through down-regulation of interleukin-6 receptors but through up-regulation of p21. Neoplasia 1999;94:251-9.
34. Guschin D, Rogers N, Briscoe J, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 1995;14:1421-9.
35. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003;22:3424-30.
36. Ohnishi S, Ohnami S, Laub F, et al. Down-regulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun 2003;308:251-6.
37. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
38. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. PNAS 2000;97:228-33.
39. De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-57.
40. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targteting FGFR3 in multiple myeloma inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004;18:962-6.
41. Paterson JL, Li Z, Wen XY, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004;124:595-603.
42. Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004;103:3521-8.
43. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in comlex with inhibitors. Science 1997;276:955-60.
44. Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001;114: 362-4.